Chardan Capital Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $30.00
D Molecular Therapeutics (NASDAQ:FDMT – Free Report) had its price target decreased by Chardan Capital from $39.00 to $30.00 in a report released on Tuesday,Benzinga reports. Chardan Capital currently ...
HC Wainwright Reiterates “Buy” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)
D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating reiterated by equities researchers at ...
AI Uncovers Hidden Genetic Clues That Challenge COVID-19’s Origins
A surprising new study suggests that COVID-19 may not have originated from bats or pangolins, but rather from a rare fusion ...
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 Analysts
In the assessment of 12-month price targets, analysts unveil insights for 4D Molecular Therapeutics, presenting an average ...